Iberiabank Corp Buys 14,093 Shares of Pfizer Inc. (PFE)
Iberiabank Corp raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 172,937 shares of the biopharmaceutical company’s stock after acquiring an additional 14,093 shares during the quarter. Pfizer makes up about 1.0% of Iberiabank Corp’s portfolio, making the stock its 28th biggest position. Iberiabank Corp’s holdings in Pfizer were worth $6,180,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer in the 2nd quarter worth $103,000. Herndon Capital Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $120,000. Private Vista LLC boosted its position in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares in the last quarter. Finally, Lipe & Dalton boosted its position in shares of Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares in the last quarter. 70.06% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Nord/LB restated a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Morgan Stanley set a $41.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Berenberg Bank set a $36.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $39.45.
Pfizer Inc. (NYSE PFE) opened at $34.66 on Tuesday. The stock has a market capitalization of $206,600.00, a price-to-earnings ratio of 9.85, a P/E/G ratio of 1.93 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the business posted $0.47 EPS. analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.92%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 38.64%.
Pfizer declared that its board has authorized a share buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/iberiabank-corp-buys-14093-shares-of-pfizer-inc-pfe/1862833.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.